Authors: Ayu Visita Dwi*, Didik Hasmono
Department of Clinical Pharmacy, Faculty of Pharmacy,
Airlangga University, Dharmawangsa Dalam, 60286 Surabaya, Indonesia
*E-mail : ayuvisita@yahoo.com
Abstract
Ischemic stroke is a focal neurological disorder that occurs as a result of insufficient or disconnected blood flow to the area of the brain, usually caused by clogged arteries. The sudden blockage of blood flow to the brain causes tissue hypoxia and triggers an inflammatory cascade. The point of ischemic can be seen from the irreversible tissue damage. Ischemic on penumbra represent tissue that functionally disturbed but structurally intact and therefore, potentially salvageable. Salvaging this tissue by restoring flow to non-ischemic levels is the goal of reperfusion therapy in acute stroke. One type of drug that is often used in ischemic stroke therapy such as thrombolysis. Tenecteplase is one of the third generation thrombolytics had their chemical structure slightly altered to increase fibrin specificity and to increase half-life. Tenecteplase was associated with significantly better reperfusion at 24 hr (TNK = 79,3%; t-PA = 55%) and clinical outcomes than alteplase in patients with stroke who were selected on the basis of CT perfusion imaging
Keywords: Tenecteplase, Thrombolysis, Acute Ischemic Stroke
